MPI-ANGIO

Magnetic Particle Imaging for Safe Angiography

 Coordinatore Bilkent Üniversitesi 

 Organization address address: ESKISEHIR YOLU 8 KM
city: ANKARA
postcode: TR-06800

contact info
Titolo: Prof.
Nome: Abdullah
Cognome: Atalar
Email: send email
Telefono: +90 312 2901200
Fax: +90 312 2664161

 Nazionalità Coordinatore Turkey [TR]
 Totale costo 100˙000 €
 EC contributo 100˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2013-CIG
 Funding Scheme MC-CIG
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2017-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    Nome Ente NON disponibile

 Organization address address: ESKISEHIR YOLU 8 KM
city: ANKARA
postcode: TR-06800

contact info
Titolo: Prof.
Nome: Abdullah
Cognome: Atalar
Email: send email
Telefono: +90 312 2901200
Fax: +90 312 2664161

TR (ANKARA) coordinator 100˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

angiography    mri       scanners    disease    hardware    agent    contrast    promise    ray    patients    ckd    ct    imaging    mpi   

 Obiettivo del progetto (Objective)

'Magnetic Particle Imaging (MPI) is a new imaging modality with the ideal image contrast for angiography that uses completely different hardware from X-ray, CT, or MRI. MPI is now at an exciting stage of development similar to where MRI was in the early 1980s. Currently, there are no commercially available MPI scanners. Only a handful of prototype small animal MPI scanners have been constructed worldwide in research environments. Yet, there is already great promise for diagnostic application of MPI for the three top mortality diseases in the world: cardiovascular disease (25% of all deaths), cancer (23%), and stroke (5%). MPI angiography shows great promise as a noninvasive, non-ionizing replacement for the millions of high-risk iodinated contrast studies performed annually. The contrast agent used in MPI, Super-Paramagnetic Iron Oxide (SPIO) nanoparticles, has been found to be extremely safe, even for chronic kidney disease (CKD) patients whose kidneys cannot safely excrete iodine contrast agents of X-ray and CT angiography. Indeed, SPIOs are now EU approved to treat anemia in CKD patients. With this proposal, Dr. Saritas will begin development of Turkey’s first MPI laboratory, and transfer her MPI expertise acquired at University of California, Berkeley to the scientific community in Europe. MPI-ANGIO project proposes several innovations in MPI hardware, contrast agent and pulse sequences to improve MPI’s spatial and temporal resolutions, now ~2 mm pixels and 7-minute scan time, to a much sharper 300-micron resolution at 2-4 frames/second.'

Altri progetti dello stesso programma (FP7-PEOPLE)

YTANIZAWA (2008)

Dissecting dynamic monoaminergic nervous system in C. elegans with genetically-encoded neuron activator protein channelrhodopsin-2

Read More  

DAD (2008)

Anomaly detection in distributed networks

Read More  

PALM TCR COMPLEXES (2012)

Studying the Structure and Dynamics of TCR nucleated Complexes at the single molecule level

Read More